Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18588481 | 0.82 | POLR1A (0.48) | CHRNB2CHRNA5CHRNA7CHRNA4KMT2A | |
| SCHEMBL47618 | 0.77 | SIGMAR1 (0.53) | HRH3 | |
| SCHEMBL47616 | 0.76 | SIGMAR1 (0.52) | HRH3 | |
| SCHEMBL12900867 | 0.76 | CHRNB2 (0.41) | CHRNB2CHRNA5CHRNA7CHRNA4HRH3 | |
| SCHEMBL47643 | 0.72 | KDM4E (0.40) | HCRTR1HCRTR2KMT2A | |
| SCHEMBL14713916 | 0.70 | CHRNB2 (0.40) | CHRNB2CHRNA5CHRNA7CHRNA4HRH3 | |
| SCHEMBL20356852 | 0.70 | POLR1A (0.46) | CHRNB2CHRNA5CHRNA7CHRNA4KMT2A | |
| SCHEMBL19710769 | 0.69 | PARP1 (0.53) | CHRNB2CHRNA5CHRNA7CHRNA4CHRM3 | |
| SCHEMBL18588486 | 0.69 | KDM4E (0.49) | KMT2A | |
| SCHEMBL19849442 | 0.69 | POLR1A (0.50) | CHRNB2CHRNA5CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
| US-9511122-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-12-06 | — | — | US | disclosed |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-9272048-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | Ascendis Phama A/S (DK) | 2014-10-30 | — | — | US | disclosed |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-08-28 | — | — | US | disclosed |
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ABCB11, SLCO1B1, SLC7A1 | CHRNB2 3452/4885CHRNA5 4033/4885CHRNA7 3632/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | CHRNB2 2309/4885CHRNA5 1623/4885CHRNA7 2044/4885 |
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | GHRHR, GHSR, GCG | CHRNB2 3794/4885CHRNA5 4133/4885CHRNA7 3394/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | CHRNB2 4025/4885CHRNA5 4203/4885CHRNA7 4069/4885 |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ADAMTS13, ADAMTS5, TNF | CHRNB2 4206/4885CHRNA5 3504/4885CHRNA7 3494/4885 |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CHRNB2 3361/4885CHRNA5 2608/4885CHRNA7 2791/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | CHRNB2 3794/4885CHRNA5 4133/4885CHRNA7 3394/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | CHRNB2 3361/4885CHRNA5 2608/4885CHRNA7 2791/4885 |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | GHRHR, GHITM, GHSR | CHRNB2 4723/4885CHRNA5 4707/4885CHRNA7 4471/4885 |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | CHRNB2 4723/4885CHRNA5 4707/4885CHRNA7 4471/4885 |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | P4HA1, CYP8B1, PAH | CHRNB2 3306/4885CHRNA5 3651/4885CHRNA7 3288/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CHRNB2 3364/4885CHRNA5 2612/4885CHRNA7 2780/4885 |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | SLC6A7, PRAP1, PELP1 | CHRNB2 4044/4885CHRNA5 4173/4885CHRNA7 3954/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | CHRNB2 3794/4885CHRNA5 4133/4885CHRNA7 3394/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | CHRNB2 4063/4885CHRNA5 4036/4885CHRNA7 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.